Skip to main content
AKBA logo

AKBA · Akebia Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track AKBA — free
$0.42 +0.01 (+3.28%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19 2.75M Avg daily vol (3M) 8.17M

Akebia Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Akebia Therapeutics, Inc. (AKBA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-05
Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript
Positive tone Large dialysis provider adoption VOICE outcomes data VOCAL study
Revenue
$36.90M
▼ 37.2% YoY
Diluted EPS
$-0.05
Gross margin
82.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Confident tone Pipeline: Prolisiguat (PROLI) in FSGS Pipeline: Ibribifus (EBRI) in rare kidney diseases VOICE trial results
Revenue
$49.13M
▼ 21.4% YoY
Diluted EPS
$-0.03
Gross margin
78.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Akebia Therapeutics, Inc. (AKBA) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Confident tone Vafcio launch performance Observed dosing protocol adoption Perlisiguat / FSGS pipeline
Revenue
$53.54M
▼ 6.6% YoY
Diluted EPS
$-0.03
▼ 200% YoY
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Positive tone Vafseo Commercial Launch Q4 2025 Demand Softness Post-Marketing Studies (VOCAL/VOICE)
Revenue
$57.62M*
▲ 23.9% YoY
Gross margin
78.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Positive tone Dialysis provider partnerships and access expansion Operational and adherence challenges Clinical data and standard of care goal
Revenue
$58.77M
▲ 57% YoY
Diluted EPS
$0.00
Gross margin
84.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Confident tone Vafseo launch progress Auryxia legacy franchise and generic risk DaVita and large dialysis provider access
Revenue
$62.47M
▲ 43.1% YoY
Diluted EPS
$0.00
Gross margin
84.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Confident tone Dialysis organization onboarding and large-provider pilots Vafseo (vadadustat) US launch and net product revenues Refills, persistence, and dose titration
Revenue
$57.34M
▲ 75.8% YoY
Diluted EPS
$0.03
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Confident tone Vafseo U.S. launch performance Reimbursement mix (Medicare, Medicare Advantage, commercial) Dialysis organization access and contracting
Revenue
$46.50M*
▼ 17.3% YoY
Gross margin
56.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Confident tone Vafseo launch preparation Dialysis contracting and access Prescriber demand and awareness
Revenue
$37.43M
▼ 11% YoY
Diluted EPS
$-0.10
Gross margin
62.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call
Revenue
$43.65M
▼ 22.6% YoY
Diluted EPS
$-0.04
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Confident tone Vafseo launch execution Auryxia entering the bundle Clinical data and publications
Revenue
$32.61M
▼ 18.5% YoY
Diluted EPS
$-0.09
Gross margin
64.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Akebia Therapeutics, Inc. (AKBA) Q4 2023 Earnings Call
Revenue
$56.20M*
▲ 0.9% YoY
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript
Revenue
$42.05M
▼ 13.7% YoY
Diluted EPS
$-0.08
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-25
Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
Revenue
$56.38M
▼ 55.4% YoY
Diluted EPS
$-0.06
▼ 140% YoY
Gross margin
69.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript
Revenue
$40.01M
▼ 35.2% YoY
Diluted EPS
$-0.15
Gross margin
49.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Akebia Therapeutics, Inc. (AKBA) Q4 2022 Earnings Call Transcript
Revenue
$55.71M*
▼ 3.4% YoY
Gross margin
104.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript
Revenue
$48.71M
▼ 0.1% YoY
Diluted EPS
$-0.29
Gross margin
21.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Akebia Therapeutics, Inc. (AKBA) Q2 2022 Earnings Call Transcript
Revenue
$126.36M
▲ 138.8% YoY
Diluted EPS
$0.15
Gross margin
85.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2022 Earnings Call Transcript
Revenue
$61.70M
▲ 18% YoY
Diluted EPS
$-0.35
Gross margin
49.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Akebia Therapeutics, Inc. (AKBA) Q3 2021 Earnings Call Transcript
Revenue
$48.76M
▼ 18.7% YoY
Diluted EPS
$-0.34
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2021 Earnings Call Transcript
Revenue
$52.91M
▼ 41.3% YoY
Diluted EPS
$-0.51
Gross margin
0.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Akebia Therapeutics, Inc. (AKBA) Q1 2021 Earnings Call Transcript
Revenue
$52.30M
▼ 40.9% YoY
Diluted EPS
$-0.45
Gross margin
33.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Akebia Therapeutics, Inc. (AKBA) Q4 2020 Earnings Call Transcript
Revenue
$56.04M*
▼ 19.4% YoY
Gross margin
-12.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Akebia Therapeutics, Inc. (AKBA) Q3 2020 Earnings Call Transcript
Revenue
$59.99M
▼ 34.8% YoY
Diluted EPS
$-0.42
Gross margin
49.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Akebia Therapeutics, Inc. (AKBA) Q2 2020 Earnings Call
Revenue
$90.14M
▼ 10.6% YoY
Diluted EPS
$-1.28
Gross margin
-93.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Akebia Therapeutics, Inc. (AKBA) Q1 2020 Earnings Call Transcript
Revenue
$88.48M
▲ 21.8% YoY
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Akebia Therapeutics, Inc. (AKBA) Q4 2019 Earnings Call
Revenue
$69.56M*
▲ 16.2% YoY
Gross margin
45.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 157 filings 140 filers Visit website Investor relations